Abstract

 Comparative evidence supports that droperidol is as effective as haloperidol and olanzapine for the sedation of adult patients with uncontrolled aggression, anxiety, or violent behaviour in acute care settings, and a limited quantity of evidence supports the superiority of droperidol over ziprasidone and lorazepam monotherapies.
 There are no statistically significant differences in adverse event frequency or severity in adult patients treated with droperidol compared with haloperidol or olanzapine.
 Guidelines published in 2015 support the safety and efficacy of droperidol treatment for agitation based on high-quality relevant evidence.
 These guidelines found insufficient evidence to support electrocardiogram or telemetry monitoring of patients who were administered less than 2.5 mg of droperidol.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
